MorphoSys Strengthens Clinical Development Organization with Three Management Appointments
News Dec 23, 2013
MorphoSys AG has announced that it has completed the expansion of its senior clinical development team by appointing Dr. Gabriele Elbl as Head of Regulatory Affairs, Dr. Ludger Langer as Head of Clinical Operations and Project Management and most recently Dr. Steffen Heeger as Head of Clinical Research.
Gabriele Elbl joined MorphoSys after working for more than 20 years in small and large pharmaceutical companies. During this time she gained a deep understanding of all regulatory aspects of product development, both for the US and the EU.
Dr. Elbl has extensive experience of development programs for biologics through interactions with both the American Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Most recently she held the position of Senior Vice President, Regulatory Affairs at Wilex AG, Munich.
Prior to that she worked as a Scientific Administrator at the EMA, London, and served as Head of Pharmaceutical Department at Sanofi Winthrop in Munich. Dr. Elbl studied pharmacy and received a PhD in Pharmaceutical Biology from the Ludwig-Maximilian-University, Munich.
Ludger Langer joined MorphoSys from PRA International. He brings almost 20 years of clinical operations and project management experience to MorphoSys. Dr. Langer held several positions of increasing seniority in Clinical Operations and Project Management with a focus on planning and execution of multiregional clinical trials.
Prior to joining MorphoSys, Dr. Langer was Vice President, Clinical Operations, Europe, Asia-Pacific and Africa at PRA International. Dr. Langer studied pharmacy and received a PhD from the Goethe University, Frankfurt/Main.
Steffen Heeger is an oncologist with deep experience in oncology drug development from his past ten years at Merck Serono, where he was Head of Medical Affairs and where he led the Global Clinical Development Team for Erbitux®. Dr. Heeger studied Medicine in Freiburg, Heidelberg and Mannheim and continued his medical training at the Clinic of Hematology/Oncology of the University of Heidelberg.
During this time he was also a scientist at the German Cancer Research Center (DKFZ) in Heidelberg where he worked on the development of antibody conjugates. He received a PhD in Medicine from the University of Heidelberg.
"We are very pleased to have gained three outstanding individuals for these key positions within the MorphoSys development organization," explained Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "The appointment of Gabriele Elbl and Ludger Langer earlier this year and most recently Steffen Heeger already had a significant impact on our development capabilities and underscores our strong commitment to the further expansion, development and commercialization of our proprietary drug portfolio."
Being Born During a Flu Pandemic May Increase Your Risk of Death During Another Flu PandemicNews
While past exposure to influenza A viruses often builds immunity to similar, and sometimes different, strains of the virus, researchers are calling for more attention to exceptions to that rule.READ MORE
Glythera Appoints Chief Scientific Officer and Strengthens SABNews
Dr Robert Lutz appointed as CSO to support development of next-generation PermaLink® Antibody Drug Conjugates. Dr Jon Roffey appointed to Scientific Advisory Board.READ MORE
Stainless Steel That Is More Resistant to BacteriaNews
Stainless steel is widely used in surgical instruments and implants but over time, implants can be rejected by the body and in unhygienic surgical environments, steel may not adequately resist the accumulation of harmful bacteria. However, scientists have now developed a way to modify the surface of the stainless steel by creating a set of pores at the nanoscale. The improved material could benefit the food and beverage industry as well as medicine.READ MORE